Eosinophilic Esophagitis (EoE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Eosinophilic Esophagitis (EoE) Market Outlook
Thelansis’s “Eosinophilic Esophagitis
(EoE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast
Report – 2024 To 2034" covers disease overview, epidemiology, drug
utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Eosinophilic Esophagitis (EoE)
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
Eosinophilic
Esophagitis (EoE) Overview
Eosinophilic
Esophagitis (EoE), also known as the “asthma of the esophagus,” is a chronic
condition rooted in allergies and immune responses. It shares numerous clinical
and pathophysiological features with asthma. This ailment is characterized by
inflammation in the esophagus, making it an atopic inflammatory disorder of
this organ. Age-related variations in how it manifests have been observed in
children and adults. The most frequent initial symptoms in adults include
dysphagia, food blockages, heartburn, and chest pain. Strikingly, about 50% of
adult patients who initially report food blockages are eventually diagnosed
with EoE. In contrast, children tend to exhibit vomiting, heartburn,
regurgitation, emesis, and abdominal pain more frequently. Dysphagia and food
blockages, typical adult complaints, are rarely seen in younger children but
become more common in individuals over 12. The gold standard for diagnosing EoE
relies on biopsy results showing increased eosinophils within the esophageal
epithelium without concurrent eosinophilic infiltration in the stomach or
duodenum. Most EoE patients do not respond well to acid-suppression therapy,
and up to 75% of them have a personal or family history of atopic conditions
such as asthma, eczema, and rhinitis, as well as allergies to environmental
factors or foods.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment